| Stage | MDT | % of rev | MMED | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $9.8B | 100.00% | $843M | 100.00% | MDT ×11.57 |
| Gross profit | $6.3B | 64.99% | $465M | 55.16% | MDT +9.8pp |
| Operating income | $1.8B | 18.08% | $5M | 0.59% | MDT +17.5pp |
| Pre-tax income | $1.8B | 18.13% | $4M | 0.47% | MDT +17.7pp |
| Net income | $1.5B | 15.16% | $0 | 0.00% | MDT +15.2pp |
| Stage | MDT | MMED | Gap · A − B |
|---|---|---|---|
| Revenue | $9.8B100.00% | $843M100.00% | MDT ×11.57 |
| Gross profit | 64.99%$6.3B | 55.16%$465M | MDT +9.8pp |
| Operating income | 18.08%$1.8B | 0.59%$5M | MDT +17.5pp |
| Pre-tax income | 18.13%$1.8B | 0.47%$4M | MDT +17.7pp |
| Net income |
| 15.16%$1.5B |
| 0.00%$0 |
| MDT +15.2pp |
No shared counterparties.